Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
PubWeight™: 0.75‹?›
Published in PLoS One on October 24, 2017
Authors
Alberto C Guardo1, Carmen Elena Gómez2, Vicens Díaz-Brito3, Judit Pich3, Joan Albert Arnaiz3, Beatriz Perdiguero2, Juan García-Arriaza2, Nuria González4, Carlos O S Sorzano2, Laura Jiménez4, José Luis Jiménez5, María Ángeles Muñoz-Fernández5, José M Gatell3, José Alcamí4, Mariano Esteban2, Juan Carlos López Bernaldo de Quirós5, Felipe García3, Montserrat Plana1, RISVAC02boost study
Author Affiliations
1: Immunopathology and Cellular Immunology, AIDS Research Group, IDIBAPS, Hospital Clínic, University of Barcelona, Barcelona, Spain.
2: Centro Nacional de Biotecnología, CSIC, Madrid, Spain.
3: Infectious Diseases Unit, Hospital Clínic, IDIBAPS, University of Barcelona, Spain.
4: AIDS Immunopathogenesis Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.
5: Sección Inmunología, Laboratorio InmunoBiología Molecular, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Spanish HIV HGM Biobank, Networking Research Center on Bioengineering, Biomaterials & Nanomedicine (CIBERBBN), Madrid, Spain.
Articles by these authors ⇆